Vietnam Breast Cancer Therapeutics Market Report 2022 to 2030

Vietnam Breast Cancer Therapeutics Market Analysis

$ 3999

The sharp increase in breast cancer cases and introduction of advanced therapeutics for the treatment of breast cancer has contributed significantly to the growth of Vietnam breast cancer therapeutics market from $91 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the period 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. ImexPharm Pharmaceutical Joint Stock Company, Merck, and Syndax are some of the leading companies in the Vietnam breast cancer therapeutics market.

ID: IN10VNPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Parul Choudhary

Buy Now

Vietnam Breast Cancer Therapeutics Market Executive Analysis

The Vietnam breast cancer therapeutics market size is at around $91 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. From $16.1 Bn in 2017 to $20 Bn in 2021, healthcare spending in Vietnam increased steadily. It is expected to reach $23.3 Bn in 2025 and $33.8 Bn in 2030. The government's initiatives to make healthcare more accessible and cheaper, the ageing population of the nation, increased awareness of healthcare needs, and rising incomes all contribute to this expansion. Vietnam, once among the world's poorest nations, has developed into a lower-middle-income nation with a GDP per capita of $3694.02 Bn in 2021. The World Economic Outlook of the International Monetary Fund (IMF) estimates that Vietnam's GDP would be about US$368 Bn in 2021, ranking it as the fifth-largest economy in Southeast Asia and the 41st in the entire world. Vietnam is a low-income country with an annual wage per capita of US$3,200 and a voluntary social health insurance contribution from individuals and their households of about US$20.00.

At 23 per 100,000 women, Vietnam has a very low age-standardized incidence rate for breast cancer. 3 compared to the 120 per 100,000 women recorded in wealthy Western nations like Australia and the US. Although this rate has been steady or declining in the developed world, it has climbed in Vietnam by more than a factor of two over the past 20 years, making it the most often diagnosed cancer in Vietnamese women. While there is a dearth of qualitative data, studies show that breast cancer in Vietnam tends to be detected at an advanced stage. This is likely owing to low levels of awareness of breast cancer symptoms and barriers to accessing screening services. For the years 2020–2025, the Vietnam Medical Association and Roche Vietnam inked an agreement to expand high-risk breast cancer patients access to advanced therapeutics in Vietnam. The Vietnam Medical Association will carry out the five-year project with assistance from Roche Vietnam. It aims to raise the proportion of women who detect breast cancer early and the number of high-risk patients who have access to advanced therapeutics. The project's primary goals are to increase early diagnoses at participating hospitals and to increase public awareness of breast cancer. In order to create a data repository for the diagnosis and treatment of breast cancer, it will also aid in improving the capability for breast cancer diagnosis and treatment and optimizing the current database from the National Cancer Institute and Vietnam Social Security.

vietnam breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

Vietnam has seen a sharp increase in breast cancer cases over the past ten years, and they now account for an equal share of the global incidence. This can be linked to a number of things, including aging populations and changing lifestyle preferences. The planned release of biosimilar versions of trastuzumab and bevacizumab [Roche's Avastin] will lead to more patients receiving treatment with biosimilars, expanding the treatable pool for targeted therapy in nations like Vietnam where affordability is a limiting factor.

Market Restraints

Some of the major obstacles to market expansion in Vietnam are the lack of access to modern pharmaceuticals, the high price of some targeted therapies, as well as hormonal therapy. The development of the breast cancer treatment market in Vietnam may be hampered by insufficient healthcare infrastructure and reimbursement regulations.

Competitive Landscape

Key Players

DHG Pharma (VNM)
Traphaco (VNM)
Pymepharco (VNM)
ImexPharm (VNM)
Merck
Syndax
MacroGenics
ImmunoGen
Santen Pharma
Celgene
Oncothyreon

Healthcare Policies and Regulatory Landscape

The establishment of social health insurance in Vietnam in 1992 has led to its current status as the primary source of public funding for medical treatment. Currently, 87% of the population is covered by health insurance. Through strategic purchasing, there is a need to increase equity and effectiveness in the utilization of the fund. The social health insurance program, which is compulsory for all citizens and covers a wide range of medical treatments, including the treatment of breast cancer, is the basis of Vietnam's reimbursement system. The government determines the reimbursement rates, which are based on a pricing structure for various services and procedures. Co-payments, which patients are required to make, cover a % of the cost of their care, with the government covering the rest. Many patients must pay more out of pocket because the reimbursement rate is frequently low.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.